Analysts Anticipate 14% Upside For SMLF
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2025
0mins
Should l Buy BBIO?
Source: NASDAQ.COM
ETF Analysis: The iShares U.S. Small-Cap Equity Factor ETF (SMLF) has an implied analyst target price of $81.40, indicating a potential upside of 14% from its current trading price of $71.40.
Stock Performance Insights: Notable underlying holdings such as IHS Holding Ltd, BridgeBio Pharma Inc, and PTC Therapeutics Inc show significant upside potential based on analyst target prices, raising questions about the validity of these targets amidst market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 76.060
Low
85.00
Averages
98.50
High
157.00
Current: 76.060
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
- Clinical Trial Results: BridgeBio Pharma's PROPEL 3 Phase 3 trial for oral infigratinib in children demonstrated a significant annualized height velocity increase, with an LS mean treatment difference of +1.74 cm/year compared to placebo, highlighting the drug's potential in treating achondroplasia.
- Statistical Significance: In a pre-specified exploratory analysis of children under 8, infigratinib showed statistical significance against placebo with an LS mean decrease of -0.05, marking a significant breakthrough in randomized trials for achondroplasia treatment.
- Regulatory Plans: BridgeBio intends to meet with regulatory authorities in the second half of 2026 to discuss plans for submitting a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib, reflecting the company's confidence in future market opportunities.
- Competitive Landscape: While BioMarin's Voxzogo is the first FDA-approved drug for achondroplasia, the positive results from BridgeBio's infigratinib clinical trials may shift the competitive dynamics and enhance the company's position in the rare disease market.
See More
BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT
Positive Trial Results: BridgeBio's drug for treating an oral genetic disorder has shown a 10.44% improvement in late-stage trial results.
Impact on Patients: The positive outcomes from the trial suggest potential benefits for patients suffering from this specific genetic condition.
See More
BridgeBio Pharma Shares Surge 13% After Successful Phase 3 Trial of Infigratinib
- Clinical Trial Success: BridgeBio Pharma reported success in its pivotal Phase 3 trial for infigratinib, with topline data indicating that the annualized height velocity (AAV) met the primary endpoint over 52 weeks, suggesting strong potential for market performance.
- Key Secondary Endpoints Achieved: The global trial also met several key secondary endpoints, including changes in height Z-scores, indicating significant potential for the drug to improve patient height, thereby enhancing the company's competitive position in the rare disease market.
- Good Safety Profile: No serious adverse events or trial discontinuations were reported, demonstrating the good tolerability of infigratinib, which may bolster regulatory confidence in the upcoming drug application submissions.
- Future Development Plans: BridgeBio intends to meet with regulators in H2 2026 to discuss plans for New Drug Applications in the U.S. and EU, while also expediting the development of infigratinib for hypochondroplasia, reflecting the company's ongoing investment and strategic focus in this area.
See More
BridgeBio Reports Positive Phase-3 Data for Infigratinib
- Clinical Trial Results: BridgeBio Pharma's global PROPEL 3 trial, conducted over one year on children aged 3 to under 18, demonstrated that the experimental drug infigratinib significantly improved growth outcomes, achieving its primary study goal.
- Height Velocity Increase: Children receiving infigratinib experienced an average annualized height velocity increase of over 2 centimeters compared to the placebo group, indicating the drug's effectiveness in promoting growth, which holds significant clinical implications.
- Positive Market Reaction: Following the announcement of encouraging clinical trial results, BridgeBio Pharma's stock surged over 17% in Thursday's premarket trading, reflecting investor optimism regarding the drug's potential market value.
- Future Development Potential: The study results not only lay the groundwork for further development of infigratinib but may also open new market opportunities for BridgeBio in the treatment of pediatric growth disorders, enhancing the company's competitive position.
See More
BridgeBio Reports Positive Results from PROPEL 3 Study
- Clinical Trial Success: The PROPEL 3 study successfully met its primary endpoint at Week 52, demonstrating a significant increase in annualized height velocity (AHV) with a mean treatment difference of +2.10 cm/year compared to placebo (p<0.0001), highlighting the drug's potential importance in pediatric growth.
- Secondary Endpoint Breakthrough: In a pre-specified exploratory analysis, oral infigratinib achieved the first statistically significant improvement in body proportionality in children under 8 years old, showing an LS mean treatment difference of -0.05 against placebo (p<0.05), providing new clinical evidence for treatment.
- Good Safety Profile: Oral infigratinib was well tolerated in the trial, with no discontinuations or serious adverse events related to the study drug, and only 3 cases (4%) of mild and transient hyperphosphatemia, indicating its potential for use in children.
- Future Development Plans: BridgeBio plans to submit a New Drug Application (NDA) and Marketing Authorization Application (MAA) in the second half of 2026 and accelerate the development of infigratinib for hypochondroplasia, demonstrating the company's commitment to addressing unmet medical needs.
See More
U.S. Markets End Thursday in Decline; Estee Lauder Experienced the Largest Drop
- Stock Market Decline: U.S. stock indexes experienced a drop on Thursday, with the overall market declining by 1.59%.
- Sector Performance: The S&P 500 index fell by 1.23%, while another index decreased by 1.20%.
See More
BridgeBio Pharma Stock Soars on Positive Clinical Trial Results
- Clinical Trial Results: BridgeBio Pharma's PROPEL 3 Phase 3 trial for oral infigratinib in children demonstrated a significant annualized height velocity increase, with an LS mean treatment difference of +1.74 cm/year compared to placebo, highlighting the drug's potential in treating achondroplasia.
- Statistical Significance: In a pre-specified exploratory analysis of children under 8, infigratinib showed statistical significance against placebo with an LS mean decrease of -0.05, marking a significant breakthrough in randomized trials for achondroplasia treatment.
- Regulatory Plans: BridgeBio intends to meet with regulatory authorities in the second half of 2026 to discuss plans for submitting a New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib, reflecting the company's confidence in future market opportunities.
- Competitive Landscape: While BioMarin's Voxzogo is the first FDA-approved drug for achondroplasia, the positive results from BridgeBio's infigratinib clinical trials may shift the competitive dynamics and enhance the company's position in the rare disease market.
See More
BRIDGEBIO STOCK RISES 10.44% FOLLOWING FAVORABLE LATE-STAGE TRIAL OUTCOMES FOR ORAL GENETIC DISORDER TREATMENT
Positive Trial Results: BridgeBio's drug for treating an oral genetic disorder has shown a 10.44% improvement in late-stage trial results.
Impact on Patients: The positive outcomes from the trial suggest potential benefits for patients suffering from this specific genetic condition.
See More
BridgeBio Pharma Shares Surge 13% After Successful Phase 3 Trial of Infigratinib
- Clinical Trial Success: BridgeBio Pharma reported success in its pivotal Phase 3 trial for infigratinib, with topline data indicating that the annualized height velocity (AAV) met the primary endpoint over 52 weeks, suggesting strong potential for market performance.
- Key Secondary Endpoints Achieved: The global trial also met several key secondary endpoints, including changes in height Z-scores, indicating significant potential for the drug to improve patient height, thereby enhancing the company's competitive position in the rare disease market.
- Good Safety Profile: No serious adverse events or trial discontinuations were reported, demonstrating the good tolerability of infigratinib, which may bolster regulatory confidence in the upcoming drug application submissions.
- Future Development Plans: BridgeBio intends to meet with regulators in H2 2026 to discuss plans for New Drug Applications in the U.S. and EU, while also expediting the development of infigratinib for hypochondroplasia, reflecting the company's ongoing investment and strategic focus in this area.
See More
BridgeBio Reports Positive Phase-3 Data for Infigratinib
- Clinical Trial Results: BridgeBio Pharma's global PROPEL 3 trial, conducted over one year on children aged 3 to under 18, demonstrated that the experimental drug infigratinib significantly improved growth outcomes, achieving its primary study goal.
- Height Velocity Increase: Children receiving infigratinib experienced an average annualized height velocity increase of over 2 centimeters compared to the placebo group, indicating the drug's effectiveness in promoting growth, which holds significant clinical implications.
- Positive Market Reaction: Following the announcement of encouraging clinical trial results, BridgeBio Pharma's stock surged over 17% in Thursday's premarket trading, reflecting investor optimism regarding the drug's potential market value.
- Future Development Potential: The study results not only lay the groundwork for further development of infigratinib but may also open new market opportunities for BridgeBio in the treatment of pediatric growth disorders, enhancing the company's competitive position.
See More
BridgeBio Reports Positive Results from PROPEL 3 Study
- Clinical Trial Success: The PROPEL 3 study successfully met its primary endpoint at Week 52, demonstrating a significant increase in annualized height velocity (AHV) with a mean treatment difference of +2.10 cm/year compared to placebo (p<0.0001), highlighting the drug's potential importance in pediatric growth.
- Secondary Endpoint Breakthrough: In a pre-specified exploratory analysis, oral infigratinib achieved the first statistically significant improvement in body proportionality in children under 8 years old, showing an LS mean treatment difference of -0.05 against placebo (p<0.05), providing new clinical evidence for treatment.
- Good Safety Profile: Oral infigratinib was well tolerated in the trial, with no discontinuations or serious adverse events related to the study drug, and only 3 cases (4%) of mild and transient hyperphosphatemia, indicating its potential for use in children.
- Future Development Plans: BridgeBio plans to submit a New Drug Application (NDA) and Marketing Authorization Application (MAA) in the second half of 2026 and accelerate the development of infigratinib for hypochondroplasia, demonstrating the company's commitment to addressing unmet medical needs.
See More
U.S. Markets End Thursday in Decline; Estee Lauder Experienced the Largest Drop
- Stock Market Decline: U.S. stock indexes experienced a drop on Thursday, with the overall market declining by 1.59%.
- Sector Performance: The S&P 500 index fell by 1.23%, while another index decreased by 1.20%.
See More
